Research ArticleOncology
Treatment Monitoring of Immunotherapy and Targeted Therapy Using 18F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences
Norbert Galldiks, Diana S.Y. Abdulla, Matthias Scheffler, Fabian Wolpert, Jan-Michael Werner, Martin Hüllner, Gabriele Stoffels, Viola Schweinsberg, Max Schlaak, Nicole Kreuzberg, Jennifer Landsberg, Philipp Lohmann, Garry Ceccon, Christian Baues, Maike Trommer, Eren Celik, Maximilian I. Ruge, Martin Kocher, Simone Marnitz, Gereon R. Fink, Jörg-Christian Tonn, Michael Weller, Karl-Josef Langen, Jürgen Wolf and Cornelia Mauch
Journal of Nuclear Medicine April 2021, 62 (4) 464-470; DOI: https://doi.org/10.2967/jnumed.120.248278
Norbert Galldiks
1Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
3Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany
Diana S.Y. Abdulla
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
4Lung Cancer Group, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Matthias Scheffler
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
4Lung Cancer Group, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Fabian Wolpert
5Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
Jan-Michael Werner
1Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Martin Hüllner
6Department of Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland
Gabriele Stoffels
3Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany
Viola Schweinsberg
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
7Department of Dermatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Max Schlaak
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
7Department of Dermatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Nicole Kreuzberg
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
7Department of Dermatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Jennifer Landsberg
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
8Department of Dermatology, University Hospital Bonn, Bonn, Germany
Philipp Lohmann
3Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany
9Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Garry Ceccon
1Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Christian Baues
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
10Department of Radiation Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Maike Trommer
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
10Department of Radiation Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Eren Celik
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
9Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Maximilian I. Ruge
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
9Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Martin Kocher
3Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany
9Department of Stereotaxy and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Simone Marnitz
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
10Department of Radiation Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Gereon R. Fink
1Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
3Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany
Jörg-Christian Tonn
11Department of Neurosurgery, University Hospital LMU Munich, Munich, Germany; and
Michael Weller
5Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
Karl-Josef Langen
3Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany
12Department of Nuclear Medicine, RWTH University Hospital Aachen, Aachen, Germany
Jürgen Wolf
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
4Lung Cancer Group, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Cornelia Mauch
2Center of Integrated Oncology, Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany
7Department of Dermatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Data supplements
HTML Page - index.htslp
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 4
April 1, 2021
Treatment Monitoring of Immunotherapy and Targeted Therapy Using 18F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences
Norbert Galldiks, Diana S.Y. Abdulla, Matthias Scheffler, Fabian Wolpert, Jan-Michael Werner, Martin Hüllner, Gabriele Stoffels, Viola Schweinsberg, Max Schlaak, Nicole Kreuzberg, Jennifer Landsberg, Philipp Lohmann, Garry Ceccon, Christian Baues, Maike Trommer, Eren Celik, Maximilian I. Ruge, Martin Kocher, Simone Marnitz, Gereon R. Fink, Jörg-Christian Tonn, Michael Weller, Karl-Josef Langen, Jürgen Wolf, Cornelia Mauch
Journal of Nuclear Medicine Apr 2021, 62 (4) 464-470; DOI: 10.2967/jnumed.120.248278
Treatment Monitoring of Immunotherapy and Targeted Therapy Using 18F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences
Norbert Galldiks, Diana S.Y. Abdulla, Matthias Scheffler, Fabian Wolpert, Jan-Michael Werner, Martin Hüllner, Gabriele Stoffels, Viola Schweinsberg, Max Schlaak, Nicole Kreuzberg, Jennifer Landsberg, Philipp Lohmann, Garry Ceccon, Christian Baues, Maike Trommer, Eren Celik, Maximilian I. Ruge, Martin Kocher, Simone Marnitz, Gereon R. Fink, Jörg-Christian Tonn, Michael Weller, Karl-Josef Langen, Jürgen Wolf, Cornelia Mauch
Journal of Nuclear Medicine Apr 2021, 62 (4) 464-470; DOI: 10.2967/jnumed.120.248278
Jump to section
Related Articles
Cited By...
- Amino Acid PET in Neurooncology
- Utility of Amino Acid PET in the Differential Diagnosis of Recurrent Brain Metastases and Treatment-Related Changes: A Meta-analysis
- Amino Acid PET in Neurooncology
- Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET